Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52,968 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting MET in NSCLC: An Ever-Expanding Territory.
Han Y, Yu Y, Miao D, Zhou M, Zhao J, Shao Z, Jin R, Le X, Li W, Xia Y. Han Y, et al. Among authors: zhao j. JTO Clin Res Rep. 2024 Jan 3;5(2):100630. doi: 10.1016/j.jtocrr.2023.100630. eCollection 2024 Feb. JTO Clin Res Rep. 2024. PMID: 38361739 Free PMC article. Review.
Silencing circATXN1 in Aging Nucleus Pulposus Cell Alleviates Intervertebral Disc Degeneration via Correcting Progerin Mislocalization.
Yu C, Zhao J, Cheng F, Chen J, Chen J, Xu H, Shi K, Xia K, Ding S, Wang K, Wang R, Chen Y, Li Y, Li H, Chen Q, Yu X, Shao F, Liang C, Li F. Yu C, et al. Among authors: zhao j. Research (Wash D C). 2024 Mar 23;7:0336. doi: 10.34133/research.0336. eCollection 2024. Research (Wash D C). 2024. PMID: 38533181 Free PMC article.
Guidelines of prevention and treatment for alcoholic liver disease (2018, China).
Li YM, Fan JG; National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Disease Expert Committee, Chinese Medical Doctor Association. Li YM, et al. J Dig Dis. 2019 Apr;20(4):174-180. doi: 10.1111/1751-2980.12687. Epub 2018 Dec 11. J Dig Dis. 2019. PMID: 30450822 No abstract available.
Author Correction: A second-generation M1-polarized CAR macrophage with antitumor efficacy.
Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, Zhang H, Zhu M, Tian L, Wang X, Su S, Xue D, Zhang S, Zhao W, Chen Y, Xie W, Zhang L, Zhu Y, Zhao J, Jiang W, Church G, Chan FK, Gao Z, Zhang J. Lei A, et al. Among authors: zhao j, zhao w. Nat Immunol. 2024 Mar;25(3):576. doi: 10.1038/s41590-023-01734-4. Nat Immunol. 2024. PMID: 38110523 No abstract available.
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S, Xiong A, Yu J, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. Ren S, et al. Among authors: zhao j. Cancer Immunol Immunother. 2024 May 10;73(7):124. doi: 10.1007/s00262-024-03715-4. Cancer Immunol Immunother. 2024. PMID: 38727837 Clinical Trial.
52,968 results
You have reached the last available page of results. Please see the User Guide for more information.